Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness
- PMID: 34554905
- DOI: 10.2174/1871526521666210923144837
Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness
Abstract
Introduction: Many potential vaccines for COVID-19 are being studied and developed. Several studies have reported on the safety and efficacy of these vaccines. This systematic review aimed to report on the current evidence concerning the feasibility and effectiveness of vaccines for COVID-19.
Methods: A systematic search was carried out utilizing the keywords in the online databases, including Scopus, Web of Science, PubMed, Embase, and Cochrane. We included both human and non-human studies because of the vaccine novelty, limiting our ability to include sufficient human studies.
Results: This review showed several SARS-CoV-2 vaccines to be currently under development using different platforms, including eight vaccines that are adenovirus-based vectors, six vaccines that are RNA-based formulations, one vaccine being DNA-based formulation, and other vaccines using other platforms, including lipid nanoparticles. Although the safety and efficacy profiles of these vaccines are still under debate, some countries have allowed for emergency use of some vaccines in at-risk populations, such as healthcare workers and the elderly.
Conclusion: It is crucial to gather as much clinically relevant evidence as possible regarding the immunogenicity, efficacy, and safety profiles of available vaccines and adhere wisely to CDC protocols and guidelines for vaccine production.
Keywords: COVID-19; SARS-CoV-2; Vaccine; diagnosis; effectiveness; feasibility; immunity; therapy; treatment.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.Front Immunol. 2021 Oct 11;12:714170. doi: 10.3389/fimmu.2021.714170. eCollection 2021. Front Immunol. 2021. PMID: 34707602 Free PMC article.
-
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1. Arch Razi Inst. 2021. PMID: 33818952 Free PMC article.
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
COVID-19 vaccines: concerns beyond protective efficacy and safety.Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5. Expert Rev Vaccines. 2021. PMID: 34180347 Review.
Cited by
-
Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review.Tanaffos. 2024 Feb;23(2):102-114. Tanaffos. 2024. PMID: 39959793 Free PMC article. Review.
-
Estimating Hidden Population Size of COVID-19 using Respondent-Driven Sampling Method - A Systematic Review.Infect Disord Drug Targets. 2024;24(6):e310124226549. doi: 10.2174/0118715265277789240110043215. Infect Disord Drug Targets. 2024. PMID: 38299412
-
Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.Hum Vaccin Immunother. 2022 Nov 30;18(5):2064134. doi: 10.1080/21645515.2022.2064134. Epub 2022 Apr 22. Hum Vaccin Immunother. 2022. PMID: 35452357 Free PMC article.
-
Determining the coverage and efficacy of the COVID-19 vaccination program at the community level in children aged 12 to 17 in Tehran.GMS Hyg Infect Control. 2024 Jan 30;19:Doc04. doi: 10.3205/dgkh000459. eCollection 2024. GMS Hyg Infect Control. 2024. PMID: 38404412 Free PMC article.
-
Public acceptability of COVID-19 vaccines and its predictors in Middle Eastern/North African (MENA) countries: a systematic review.Hum Vaccin Immunother. 2022 Nov 30;18(5):2043719. doi: 10.1080/21645515.2022.2043719. Epub 2022 Mar 23. Hum Vaccin Immunother. 2022. PMID: 35318872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous